Redhawk Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Redhawk Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,366	Closed	-$204K	–	176
2019 Q4	$204K	Buy	+1,366	New	+$186K	0.08%	162
2019 Q3	–	Sell	-1,885	Closed	-$269K	–	282
2019 Q2	$269K	Hold	1,885	–	–	0.11%	110
2019 Q1	$269K	Hold	1,885	–	–	0.14%	103
2018 Q4	$234K	Sell	1,885 -3,020	-62%	-$448K	0.14%	96
2018 Q3	$825K	Buy	+4,905	New	+$844K	0.45%	36

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Redhawk Wealth Advisors's JAZZ Position: Q1 2020 in Review

Redhawk Wealth Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 1,366 shares — an estimated $204K sold.

Redhawk Wealth Advisors first reported a position in JAZZ in Q3 2018 and held it in 5 quarters. The position peaked at $825K in Q3 2018. 407 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

Redhawk Wealth Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Redhawk Wealth Advisors sold 1,366 Jazz Pharmaceuticals shares in Q1 2020, an estimated $204K.
Redhawk Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q3 2018 and held it in 5 quarters.
Redhawk Wealth Advisors's Jazz Pharmaceuticals position peaked at $825K in Q3 2018.
407 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Redhawk Wealth Advisors's 13F filing for Q1 2020, filed 14 Apr 2020.